GenScript Biotech Corporation, a US provider of life sciences research and manufacturing services, announced on Tuesday that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner.
The company said that this move represents significant progress in its journey of fulfilling its social responsibility and progressing sustainable development, while underscoring its commitment to building a healthier, greener and more ethical industry ecosystem.
PSCI is a global association dedicated to fostering responsible value chains in the pharmaceutical and healthcare industries. It aims to address challenges within the pharmaceutical supply chain and enhance performance in areas such as ethics, human rights and labour, health and safety, environment and related management systems.
GenScript adheres fully to the PSCI principles in advancing responsible supply chain management. Through its membership in PSCI, GenScript will uphold higher ESG standards in its operations and supply chain management.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA